Testosterone is frequently used for the optimization of mid-life health. This therapy is effective and safe if accompanied by adequate counseling, before prescription, and during administration. In this opinion piece, we discuss the style and substance of medication counseling for testosterone therapy. The role and scope of counseling are highlighted, with a focus on screening, diagnosis, medication counseling, sexual counseling, and monitoring. This article should prove useful for all health care professionals.

Keywords: Androgen, androgen deficiency, andropause, hormonal replacement therapy, medication counseling, sexual counseling, testosterone

INTRODUCTION

Testosterone is indicated for the management of testosterone deficiency. While there are many etiologies of this dysfunction, the most common is age-related. Andropause, better known as (androgen deficiency in the aging male) presents with a wide variety of biomedical as well as psychosocial challenges. While some of these may be related to aging in general, others are specifically linked to a decline in testosterone levels.[1]

Metabolic disorders, such as diabetes, obesity, metabolic syndrome, obstructive sleep apnea; medical disorders such as anemia, chronic liver disease, chronic kidney disease, chronic lung disease, HIV/acquired immunodeficiency syndrome; endocrine disorders including osteoporosis, sarcopenia, pituitary disease; history of chronic corticosteroid use, anabolic androgenic substance abuse, antipsychotic/anticonvulsant therapy, gonadal radiation, and gonadal surgery can be associated with low testosterone levels.

THE ROLE OF COUNSELLING

Although various pharmacological options are available for the management of testosterone deficiency, and its associated comorbidities, counseling is an essential part of the management of andropause.[2] Counseling acts as a therapy in itself, as explained in the concept of therapeutic patient education. Counseling also improves understanding or acceptance of, and adherence to suggested therapy.[3] It improves satisfaction with treatment, enhances patient-physician bonding, and works as (value-added therapy).

THE SCOPE OF COUNSELING

Although the term counseling is defined as “the provision of professional assistance and guidance in

Address for correspondence: Dr. Sanjay Kalra, Department of Endocrinology, Bharti Hospital, Kunipura Road, Karnal - 132 001, Haryana, India. E-mail: brideknl@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKLHRPMedknow_reprints@wolterskluwer.com

How to cite this article: Kalra S, Joshi A, Dhingra A, Dutta D, Das S. Counselling for testosterone therapy in mid life men. J Mid-life Health 2022;13:185-9.
Andropause counseling includes, and overlaps with, patient education, support, advocacy, and medication counseling. Table 1 lists the various facets of andropause counseling. Many of these facets are similar to those seen with other chronic diseases. A few aspects of counseling, however, need specific attention, as they are specific to andropause. These are medication counseling for testosterone therapy and sexual counseling.

**SCREENING AND DIAGNOSIS**
Counseling begins simultaneously with screening. Though universal screening for testosterone deficiency is not recommended, assessment of testosterone adequacy should be done if symptoms, signs, or surrogate laboratory markers are suggestive. While monitoring is ideally done by measuring testosterone levels at appropriate intervals, it should be supplemented with clinical interviewing. Libido, erectile function, hemoglobin, bone mineral density, lean body mass, and depressive symptoms can be used as clinical markers for screening as well as monitoring. Validated screening tools [Table 2] can be used for monitoring of symptomatic well-being as well.

**COST BENEFIT RATIO/REALITY CHECK**
Before starting therapy, the patient should be explained regarding expected benefits, limitations, and caveats of testosterone therapy. Unfounded concerns should be allayed. At the same time, the patient should be provided with a realistic idea of which symptoms, signs, and abnormalities he can expect benefit in. There is no link of testosterone therapy with venous thromboembolism. Its impact on cognitive function, glycemic control, energy level/quality of life, and lipid health/cardiovascular health is uncertain. One must always be watchful for the potential deleterious effects on polycythemia and spermatogenesis. Some contraindications are active prostatic carcinoma, acute coronary syndromes in the past 3–6 months, and heart failure NYHA Class IV.

**MEDICATION COUNSELING**
Testosterone is the pillar of andropause management. Various preparations of testosterone are available:

---

**Table 1: Domains of andropause counseling**

| Screening and diagnosis          |
|----------------------------------|
| Description of symptoms          |
| Administration of questionnaire  |
| Counseling for accurate for testosterone estimation |
| Pretherapeutic counseling        |
| Assessment of contraindications  |
| Explanation of expected benefits, possible side effects, anticipated limitations, and cost |
| Assistance with risk-benefit analysis |
| Choice of testosterone therapy   |
| Sharing of available options: Lifestyle, testosterone, nonhormonal therapy |
| Explanation of route of administration, advantages, limitations, side effects, cost |
| Assessment of best possible option(s) |
| Choice of nonhormonal therapy    |
| Clinical assessment of musculoskeletal metabolic, sexual, psychosocial comorbidities |
| Sharing therapeutic plan for mitigation of comorbidities |
| Assistance with cost-benefit analysis and reality check in terms of expected benefits |
| Monitoring                       |
| Clinical monitoring for symptomatic well being, potential adverse effects of overdosage, indicators of suboptimal dosage |
| Reminders for regular biochemical and imaging monitoring, as indicated |
| Troubleshooting in case of unexpected clinical situations |
| Support                          |
| Psychological confidence building |
| Marriage therapy/family therapy if needed |
| “Best buddy” feeling             |
| Sexual counseling                |
| Nonpharmacological assistance    |
| Pharmacological therapy          |
| Invasive/surgical management     |

**Table 2: Questionnaires that may be used to kickstart a conversation, screen, and/or monitor testosterone deficiency**

| Aging male symptoms scale[9] |
| ANDROTEST[10] |
| ADAM[11] |
| qADAM[12] |
| MMAS[13] |
| HIS-Q[14] |

ADAM: Androgen deficiency in the aging male, qADAM: Quantitative ADAM, MMAS: Massachusetts male aging study, HIS-Q: Hypogonadism impact of symptoms questionnaire

Some of these are listed in Table 3. These formulations differ in their route of administration, onset and duration of action, potency, and expected side effects or limitations. Therefore, knowledge of the clinical pharmacology of various androgenic drugs can be utilized to craft a person-centered choice of therapy. This
knowledge forms the basis of the content of andropause counseling.

The British Society for Sexual Medicine guidelines on adult testosterone deficiency leave the choice of preparation to the patient.[16] Even for this, however, information equipoise is necessary to ensure the optimal choice of treatment modality. This can be done through detailed medication counseling. The Endocrine Society (2018) suggests patient preference, formulation pharmacokinetics, treatment burden, and cost as determinants of the choice of therapy.[7,17]

Prescription of injectable testosterone presumes the availability of qualified and experienced health-care professionals capable of administering the drug. This consideration is especially important while using testosterone undecanoate, which is injected as a 4 ml oily suspension. In case of difficulty, 2 ml of this drug can be injected into each buttock.[15]

Table 4 describes some important points which must be kept in mind while planning a person-centric testosterone therapy in andropause. Clinical response/well-being, testosterone levels, hematocrit, prostate health, (prostate-specific antigen), digital rectal examination, and prostate ultrasonography may be used to monitor testosterone therapy at regular intervals.[8,15]

Although not related to andropause, it is pertinent to mention that transgender persons (transmen) also use testosterone as gender-affirmative therapy.[18] Such persons have special needs and must be handled in a gender-friendly manner. Transmen will require just 50%–75% of normal dosage to achieve masculinization and are more susceptible to side effects such as acne.

**Sexual Counseling**

Sexual dysfunction is the sine qua non of andropause, and sexual counseling, an integral part of andropause care. Reader-friendly guidance on how to elicit a sexual history, and the steps of sexual counseling are available.[19] Tables 5 and 6 describe the style as well as the content of sexual counseling. The man in andropause, who is usually in mid-life, will require more confidence building and support from the health-care professional. A greater emphasis on metabolic and

| Route                        | Preparation                  | Dosage                    |
|------------------------------|------------------------------|---------------------------|
| Oral capsules                | Testosterone undecanoate     | 40 mg 2-3 days            |
| Percutaneous gel             | Testosterone 1% gel          | Once-daily                |
| Intramuscular injection      | Testosterone suspension      | 25-50 mg q7-14 days       |
|                             | Testosterone esters 100/250 | Q21-28 days               |
|                             | Testosterone undecanoate 1000 mg | Q 90 days             |

| Person specific need                  | Preferred preparation                      |
|---------------------------------------|--------------------------------------------|
| Efficacy: Need for immediate resolution of symptoms | IM aqueous suspension; gel |
| Safety: Fear of side effects           | Capsules, gel                              |
| Tolerability: Uncertainty about long term tolerance | Capsules, gel                              |
| Stability in testosterone levels       | IM testosterone undecanoate                |
| Intrusion: Need for lesser frequency of injections | IM testosterone undecanoate |
| Independence: Avoidance of dependence on health care professionals | Capsules, gel |
| Flexibility: Need to modulate serum levels for personal reasons | IM esters 100,250 |
| Personal preference mode of administration | As per personal choice |
| Accessibility: To health care system for injection, monitoring | As per circumstance |
| Affordability: Of various preparations | As per cost |
| Availability: Of various formulations  | As per local availability                 |
| Confidence of health-care professional | As per experience                          |

| Side effects                          |                              |
|---------------------------------------|------------------------------|
| Skin irritation                        | Avoid gels                   |
| Risk of transference to partner        | Avoid gels                   |
| Pain on injection                      | Avoid 4 ml/2 ml injections   |
| Fluctuation in mood/physical/sexual symptoms | Avoid testosterone esters |
medical optimization, as opposed to focus limited to psychosocial support, maybe in order. Counseling of the man in andropause should also include explanation of cardiac-friendly and “musculo-skeletally non demanding” ways of achieving sexual satisfaction.\[^{19}\]

Though fertility is rarely an issue in this age group, the health-care professional should enquire about the person’s needs and wishes. One may suggest contraceptive measures or fertility augmenting treatment as deemed appropriate. Counseling should also include a discussion on the prevention of sexually transmitted diseases as well as genital tract infections. The need to maintain genital hygiene, especially in men on sodium-glucose co-transporter 2 inhibitors, should also be stressed.\[^{20}\]

**SUMMARY**

Testosterone is frequently used for the optimization of mid-life health. This therapy is effective and safe if accompanied by adequate counseling, before prescription, and during administration. This article provides a comprehensive overview of testosterone counseling, and should prove useful for all health-care professionals.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Singh P. Andropause: Current concepts. Indian J Endocrinol Metab 2013;17:S621-9.
2. Brawer MK. Testosterone replacement in men with andropause: An overview. Rev Urol 2004;6 Suppl 6:S9-15.
3. Brown MT, Russel JK. Medication adherence: WHO cares? Mayo Clin Proc 2011;86:304-14.
4. Oxford English and Spanish Dictionary, Thesaurus, and Spanish to English Translator. Available from: https://www.lexico.com/definition/counsellingAs. [Last accessed on 2020 Sep 30].
5. Say RE, Thomson R. The importance of patient preferences in treatment decisions – Challenges for doctors. BMJ 2003;327:542-5.
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96.
7. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018;103:1715-44.
8. Salonia A, Rastrell G, Hackett G, Seminara SB, Huhtaniemi IT, Rey RA, et al. Pediatric and adult-onset male hypogonadism. Nat Rev Dis Primers 2019;5:38.
9. Heineman AJ, Zimmermann J, Vermeulen A, Thiel C. A new aging males’ symptoms (AMS) rating scale. Aging Male 1998;2:105-14.
10. Corona G, Mannucci E, Petrone L, Balercia G, Fisher AD, Chiarini V, et al. ANDROTEST: A structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med 2006;3:706-15.
11. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-42.
12. Mohamed O, Freundlich RE, Dakik HK, Grober ED, Najari B, Lipshtutz LI, et al. The quantitative ADAM questionnaire: A new tool in quantifying the severity of hypogonadism. Int J Impot Res 2010;22:20-4.
13. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000;53:703-11.
14. Gelhorn HL, Dashiiell-Aje E, Miller MG, DeRogatis LR, Dobs A, Seftel AD, et al. Psychometric evaluation of the hypogonadism impact of symptoms questionnaire. J Sex Med 2016;13:1737-49.
15. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol 2016;5:834-43.
16. Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N, et al. British society for sexual medicine
guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med 2017;14:1504-23.
17. Maganty A, Shoag JE, Ramasamy R. Testosterone threshold—Does one size fit all? Aging Male 2015;18:1-4.
18. Lim HH, Jang YH, Choi GY, Lee JJ, Lee ES. Gender affirmative care of transgender people: A single center’s experience in Korea. Obstet Gynecol Sci 2019;62:46-55.
19. Kalra S, Balhara YP, Baruah M, Saxena A, Makker G, Jumani D, et al. Consensus guidelines on male sexual dysfunction. J Med Nutr Nutraceuticals 2013;2:5.
20. Unnikrishnan AG, Kalra S, Purandare V, Vasnawala H. Genital infections with sodium glucose cotransporter-2 inhibitors: Occurrence and management in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab 2018;22:837-42.